Profile data is unavailable for this security.
About the company
Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research, production, and sales of human vaccines. The Company's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The Company's products include two brands: Chengda Suda and Chengda Libao.
- Revenue in CNY (TTM)1.76bn
- Net income in CNY352.53m
- Incorporated2002
- Employees1.73k
- LocationLiaoning Chengda Biotechnology Co LtdNo. 1Xinfang Street, Hunnan New DistrictSHENYANG 110179ChinaCHN
- Phone+86 2 483782632
- Fax+86 2 423789772
- Websitehttp://www.cdbio.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mayinglong Pharmaceutical Group Co Ltd | 3.42bn | 473.79m | 11.16bn | 2.88k | 23.55 | 2.89 | -- | 3.26 | 1.10 | 1.10 | 7.94 | 8.94 | 0.6648 | 6.05 | 10.01 | 1,188,102.00 | 9.35 | 10.82 | 11.58 | 13.47 | 43.86 | 41.18 | 14.07 | 14.08 | 4.06 | -- | 0.0946 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
Heilongjiang ZBD Pharmaceutical Co Ltd | 2.22bn | 522.07m | 11.16bn | 2.55k | 21.33 | 1.41 | -- | 5.04 | 0.5556 | 0.5556 | 2.36 | 8.43 | 0.1757 | 0.6759 | 0.6464 | 870,758.90 | 4.10 | 3.48 | 5.54 | 4.78 | 64.84 | 38.93 | 23.37 | 10.08 | 2.18 | -- | 0.2951 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
KPC Pharmaceuticals Inc | 7.49bn | 450.79m | 11.17bn | 5.05k | 24.85 | 2.08 | -- | 1.49 | 0.594 | 0.594 | 9.89 | 7.10 | 0.7847 | 2.43 | 2.66 | 1,482,262.00 | 4.79 | 5.42 | 8.10 | 9.13 | 41.97 | 43.68 | 6.11 | 5.70 | 1.44 | -- | 0.199 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
Guobang Pharma Ltd | 5.43bn | 659.59m | 11.48bn | 4.23k | 17.41 | 1.50 | -- | 2.11 | 1.18 | 1.18 | 9.72 | 13.70 | 0.5504 | 3.05 | 7.19 | 1,283,877.00 | 6.66 | 10.36 | 8.54 | 14.24 | 23.75 | 27.49 | 12.10 | 15.01 | 1.67 | -- | 0.1799 | 18.24 | -6.49 | 10.28 | -33.49 | 23.77 | 35.60 | -- |
Liaoning Chengda Biotechnology Co Ltd | 1.76bn | 352.53m | 11.66bn | 1.73k | 33.20 | 1.22 | -- | 6.63 | 0.8438 | 0.8438 | 4.23 | 22.93 | 0.1766 | 0.7386 | 1.48 | 1,015,870.00 | 3.54 | 10.63 | 3.66 | 11.01 | 81.24 | 85.74 | 20.04 | 39.56 | 17.34 | -- | 0.0019 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.42bn | 457.64m | 12.16bn | 8.41k | 26.66 | 1.78 | -- | 1.89 | 0.1775 | 0.1775 | 2.49 | 2.66 | 0.5903 | 2.44 | 4.39 | 762,894.60 | 4.66 | 6.77 | 6.76 | 10.50 | 52.88 | 63.24 | 7.90 | 11.10 | 1.30 | 26.89 | 0.109 | 42.32 | 12.20 | -0.8267 | 65.20 | -6.21 | -11.64 | 5.92 |
Changchun BCHT Biotechnology Co | 1.88bn | 527.23m | 12.18bn | 1.24k | 23.07 | 2.96 | -- | 6.47 | 1.28 | 1.28 | 4.56 | 9.96 | 0.394 | 0.7747 | 1.53 | 1,517,684.00 | 11.03 | 9.95 | 13.51 | 12.81 | 89.44 | 86.63 | 27.99 | 24.03 | 1.99 | -- | 0.0252 | 10.55 | 70.30 | 12.36 | 175.98 | 31.37 | 21.04 | -- |
Jiangxi Tianxin Pharmaceutical Co Ltd | 1.83bn | 491.07m | 12.34bn | 2.47k | 25.13 | 2.84 | -- | 6.75 | 1.12 | 1.12 | 4.18 | 9.93 | 0.3689 | 2.51 | 6.94 | 739,805.10 | 9.91 | -- | 10.68 | -- | 40.17 | -- | 26.86 | -- | 7.14 | -- | 0.0326 | -- | -18.34 | -- | -23.51 | -- | -- | -- |
Data as of Oct 11 2024. Currency figures normalised to Liaoning Chengda Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
GF Securities Asset Management (Guangdong) Co., Ltd.as of 11 Mar 2024 | 2.75m | 1.54% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 2.56m | 1.43% |
Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 2.29m | 1.28% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 1.04m | 0.58% |
Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 937.73k | 0.52% |
Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 890.79k | 0.50% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 738.51k | 0.41% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 620.20k | 0.35% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 595.79k | 0.33% |
Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 564.56k | 0.32% |
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.